Regina Resta is a notable inventor based in Slingersland, NY (US). She has made significant contributions to the field of cancer diagnostics, holding 2 patents that focus on determining cancer susceptibility through genetic variations.

Latest Patents

Her latest patents include a diagnostic assay for cancer susceptibility, which allows for the determination of a person's lifetime probability of developing cancer based on an allelic variation found in the 3'UTR of the prohibitin gene. This probability is influenced by the sequence at position 729, specifically whether there is a thymine (T) or a cytosine (C) present. The sequence can be determined using standard techniques, preferably through PCR amplification followed by RFLP analysis. Another significant patent is a diagnostic assay for breast cancer susceptibility, which similarly assesses the lifetime probability of a woman developing breast cancer based on the same allelic variation. This polymorphism at position 729 is also recognized as a susceptibility indicator for hereditary breast cancer in men.

Career Highlights

Regina Resta is associated with the Oklahoma Medical Research Foundation, where she continues her research and innovation in cancer diagnostics. Her work has the potential to impact many lives by providing critical information regarding cancer susceptibility.

Collaborations

Some of her notable coworkers include Eldon R Jupe and Linda F Thompson, who contribute to her research endeavors.

Conclusion

Regina Resta's innovative work in cancer susceptibility diagnostics exemplifies the importance of genetic research in medicine. Her patents reflect a commitment to advancing healthcare through scientific discovery.